View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 9, 2021updated 11 Jul 2022 2:19pm

FDA accepts stroke recurrence as second primary endpoint to DiaMedica trial

The ReMEDy2 Phase II/III trial will assess DM199 to treat AIS and address both stroke recovery as well as stroke recurrence.

The US Food and Drug Administration (FDA) has accepted the addition of stroke recurrence as a second independent primary endpoint to DiaMedica Therapeutics’ ReMEDy2 Phase II/III trial assessing DM199 to treat acute ischemic stroke (AIS).

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

DM199 is a recombinant (synthetic) human tissue kallikrein-1 (KLK1) protein that regulates many physiological processes such as oxidative stress, fibrosis, blood flow, inflammation and neurogenesis through a molecular process.

This double-blind, randomised, adaptive design placebo-controlled Phase II/III study is aimed at assessing DM199’s efficacy and safety to treat AIS.

The regulatory acceptance will allow DiaMedica to assess its DM199’s impact on physical recoveries after the acute ischemic stroke and the AIS recurrent rate as two separate primary goals.

The Phase II/III trial is studying acute ischemic stroke in patients for whom thrombolysis and/or a catheter-based procedure, mechanical thrombectomy, are not medically possible because of clot location, comorbidity risks or even time from the estimated stroke onset.

In the ReMEDy2 trial, the recovery from stroke in patients will be measured by the modified Rankin Scale (mRS) at day 90 and the rate of ischemic stroke recurrence will be assessed based on the proportion of patients experiencing recurrent AIS at day 90.

DiaMedica CEO Rick Pauls said: “The medical need to develop new and better treatments for AIS is clear. Based upon our encouraging clinical experience in our Phase 2 study, we are very pleased to be formally elevating AIS recurrence to a primary endpoint in our ReMEDy2 study.

“This provides another pathway to potential success in this trial, but more importantly, underscores the importance of evaluating DM199’s potential to reduce AIS patients’ risk of suffering a recurrent stroke, which is often more disabling and fatal.”

DiaMedica stated that the addition of ischemic stroke recurrence to the trial as a second independent primary endpoint is based on the data from the company’s ReMEDy Phase 2 study, conducted in 91 subjects.

According to this data, six patients in the placebo arm experienced strokes while there were no such cases in the DM199 arm during the 90-day follow-up period.

Excluding the patients who were earlier treated with mechanical thrombectomy, four patients experienced a recurrent ischemic stroke of the placebo arm, and all those cases were fatal while the DM199 arm faced no such event.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena